Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Royalties from “TissueBlue™” were not included in net sales because the license agreement had expired and an extension was under discussion. Research and development expenses, personnel expenses and other costs decreased year on year.
A description of matters relating to the going-concern assumption is included. Although events or conditions that raise substantial doubt exist because of continuing operating losses and negative operating cash flow, the company states that there is no material uncertainty regarding the going-concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥33 million (YoY -80.9%) |
| Operating profit | ¥-312 million |
| Ordinary income | ¥-322 million |
| Profit attributable to owners of the parent | ¥-323 million |
| Net income per share | △¥5.80 |
| Equity ratio | End of the current fiscal period 68.7% / End of previous period 66.1% |
| Total assets | ¥2,049 million |
| Net assets | ¥1,409 million |
| Cash flows from operating activities | ¥-343,950 thousand |
| Cash flows from investing activities | ¥-601,660 thousand |
| Cash flows from financing activities | ¥222,250 thousand |
| Cash and cash equivalents at end of period | ¥986,537 thousand |
| Full-year earnings forecast | Net Sales ¥300 million (YoY -22.6%) / Operating profit ¥-780 million / Ordinary income ¥-800 million / Profit attributable to owners of the parent ¥-800 million |
| Revision to Earnings Forecast | Net Sales 300 / Operating profit -780 / Ordinary income -800 / Profit attributable to owners of the parent -800 → Net Sales 300 / Operating profit -780 / Ordinary income -800 / Profit attributable to owners of the parent -800 |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥2,997 thousand |
| Breakdown of extraordinary income (loss) | Not applicable (no line items for extraordinary income or extraordinary losses were disclosed in the interim consolidated income statement) |
| Disclosure regarding the going concern assumption | A description of matters relating to the going-concern assumption is included. Although events or conditions that raise substantial doubt exist because of continuing operating losses and negative operating cash flow, the company states that there is no material uncertainty regarding the going-concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | None (no newly consolidated or excluded companies disclosed) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 57,483,412 shares |
| Treasury Shares at Period-End | 11,387 shares |
| Factors Behind Changes in Business Performance | Royalties from “TissueBlue™” were not included in net sales because the license agreement had expired and an extension was under discussion. Research and development expenses, personnel expenses and other costs decreased year on year. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The license agreement for “TissueBlue™” expired in December 2025, and details regarding an extension are currently under discussion. Accordingly, royalties from the product were not included in net sales for the interim period. Research and development expenses decreased year on year mainly because of lower development costs for “H-1337” and “DWR-2206,” while other selling, general and administrative expenses decreased mainly because of lower personnel expenses.